William C. Lineaweaver

Bedeutung für die Hirudotherapie

William Lineaweaver authored the paper that almost ended modern leech therapy in 1992 — and then authored the practical solutions that allowed it to continue. The UCSF retrospective covered 33 patients treated with medicinal leeches for venous-congested microsurgical flaps between 1985 and 1991. Six of the 33 (18%) developed culture-positive Aeromonas hydrophila wound infections, three of which compromised the flap salvage outcome. The paper, published in the Annals of Plastic Surgery in late 1992, hit microsurgical practice like a thunderclap: it forced every U.S. academic medical center using leech therapy to confront an infection rate that, until then, had been quietly dismissed as 'unusual.' Lineaweaver's contribution was that he immediately paired the documentation of the problem with a proposed solution: prophylactic ciprofloxacin or aminoglycoside therapy during leech application. The recommendation was based on antibiogram data from the six infected isolates, all of which were ciprofloxacin-susceptible. Adoption of this prophylaxis protocol across U.S. teaching hospitals between 1993 and 1996 dropped the documented infection rate from the pre-1992 baseline of 7-20% to approximately 2-4% by 2000 — and made the FDA's 2004 medical-device clearance of medicinal leeches feasible. Without the Lineaweaver prophylaxis framework, K040187 might never have been issued. Lineaweaver's parallel 1991 paper on leech use in microvascular surgery was the procedural template that codified application techniques: leech density per cm² of congested flap, replacement intervals, transfusion thresholds, and discontinuation criteria. Combined with his 1992 infection paper and his 2003 retrospective at twenty years post-protocol-introduction, his work is the canonical American foundation of modern flap-salvage hirudotherapy. ASH considers him the patron of infection-conscious leech therapy.